Eli Lilly said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing ...

The Food and Drug Administration had recently approved a new drug for the treatment of atopic dermatitis (eczema), which can ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are archrivals thanks to their dueling drugs for weight loss, Zepbound and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s ...

Stocks to Watch. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...

Politics, though controversial, this year presents one single theme that I think we can all agree on. Our government needs a ...

The Lilly Endowment Inc. keeps pouring into leaders, and Michelle Love thinks she has more she could pour out, too.

To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.

In this episode of "Shelf Portrait," comedian and host Lilly Singh gives Marie Claire a look at her eye-catching, topsy-turvy bookshelves filled with books by several of her favorite South Asian ...

Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure ...

The success of Eli Lilly’s Zepbound, a challenger to Novo’s Wegovy, has prompted comparisons to a similar scenario, when ...